{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:28Z","timestamp":1792783528104,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Supernus Pharmaceuticals Inc.","id":[{"id":"https:\/\/ror.org\/03sd6kg46","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01580-w","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T07:16:58Z","timestamp":1785050218000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree\u00ae) in Adults"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0633-5630","authenticated-orcid":false,"given":"Zhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyin","family":"Adewole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian W.","family":"Adeojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peibing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmi","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"issue":"3-4","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0014-2999(78)90291-1","volume":"52","author":"TP Blackburn","year":"1978","unstructured":"Blackburn TP, Foster GA, Greenwood DT, Howe R. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52(3\u20134):367\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1580_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0028-3908(78)90018-7","volume":"17","author":"IL Martin","year":"1978","unstructured":"Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17(6):421\u20133.","journal-title":"Neuropharmacology"},{"key":"1580_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JEP.S256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300.","journal-title":"J Exp Pharmacol"},{"key":"1580_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/JEP.S433524","volume":"16","author":"J Garcia-Olivares","year":"2024","unstructured":"Garcia-Olivares J, Yegla B, Bymaster FP, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-deficit\/hyperactivity disorder. J Exp Pharmacol. 2024;16:13\u201324.","journal-title":"J Exp Pharmacol"},{"key":"1580_CR5","volume-title":"Qelbree [package insert]","author":"PI Supernus","year":"2025","unstructured":"Supernus PI. Qelbree [package insert]. Rockville: Supernus Pharmaceuticals, Inc.; 2025."},{"issue":"3","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2125.1975.tb01577.x","volume":"2","author":"PF Bayliss","year":"1975","unstructured":"Bayliss PF, Case DE. Blood level studies with viloxazine hydrochloride in man. Br J Clin Pharmacol. 1975;2(3):209\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/00498254.2020.1767319","volume":"50","author":"C Yu","year":"2020","unstructured":"Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285\u2013300.","journal-title":"Xenobiotica"},{"issue":"11","key":"1580_CR8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/cpdd.948","volume":"10","author":"Z Wang","year":"2021","unstructured":"Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults. Clin Pharmacol Drug Dev. 2021;10(11):1365\u201374.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-024-01356-0","volume":"44","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liranso T, Maldonado-Cruz Z, Kosheleff AR, Nasser A. Impact of viloxazine extended-release capsules (Qelbree\u00ae) on select cytochrome P450 enzyme activity and evaluation of CYP2D6 genetic polymorphisms on viloxazine pharmacokinetics. Clin Drug Investig. 2024;44(5):303\u201317.","journal-title":"Clin Drug Investig"},{"key":"1580_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40261-020-00992-6","volume":"41","author":"SL Faison","year":"2020","unstructured":"Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. 2020;41:149\u201359.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1580_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/JCP.0000000000001361","volume":"41","author":"SL Faison","year":"2021","unstructured":"Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155\u201362.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00003088-199529050-00005","volume":"29","author":"DJ Morgan","year":"1995","unstructured":"Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet. 1995;29(5):370\u201391.","journal-title":"Clin Pharmacokinet"},{"key":"1580_CR13","unstructured":"FDA. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and. Accessed 9 June 2021."},{"issue":"12","key":"1580_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/cc8855","volume":"14","author":"A Slack","year":"2010","unstructured":"Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care. 2010;14(2):214.","journal-title":"Crit Care"},{"issue":"6","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003495-197713060-00001","volume":"13","author":"RM Pinder","year":"1977","unstructured":"Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13(6):401\u201321.","journal-title":"Drugs"},{"key":"1580_CR17","doi-asserted-by":"crossref","unstructured":"Nasser A, Faison SL, Liranso T, et al. Evaluation of the effect of SPN-812 (viloxazine extended-release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):20m13395.","DOI":"10.4088\/JCP.20m13395"},{"issue":"2","key":"1580_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1087054719836159","volume":"24","author":"JK Johnson","year":"2020","unstructured":"Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348\u201358.","journal-title":"J Atten Disord"},{"key":"1580_CR19","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 in the treatment of adolescents with ADHD. J Clin Psychopharmacol. 2021:41(4):370-80."},{"issue":"2","key":"1580_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.64719\/pb.4401","volume":"51","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43\u201364.","journal-title":"Psychopharmacol Bull"},{"issue":"8","key":"1580_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452\u201366.","journal-title":"Clin Ther"},{"key":"1580_CR22","doi-asserted-by":"crossref","unstructured":"Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684-700.","DOI":"10.1016\/j.clinthera.2021.01.027"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01580-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:48Z","timestamp":1790255628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01580-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01580-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial was fully sponsored by Supernus Pharmaceuticals, Inc. The protocol was designed by Supernus employees, and the study was conducted by Worldwide Clinical Trials. Z. Wang and P. Qin are employees of Supernus Pharmaceuticals, Inc. T. Adewole, L.W. Adeojo, S. Schwabe, and A. Nasser are former employees of Supernus Pharmaceuticals, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available, but reasonable requests can be directed to the corresponding author (zwang@supernus.com).","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was conducted in accordance with the Helsinki Declaration and the International Council for Harmonization Note for Guidance on Good Clinical Practice. The trial conduct was reviewed and approved by IntegReview Institutional Review Board (Austin, TX, USA); IRB approval no. 4009113.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ZW, TA, SS, and AN contributed to the original research project conception and design. ZW, TA, and AN contributed to data acquisition. ZW and PQ contributed to statistical analysis. ZW, TA, LWA, SS, and AN contributed to data interpretation. All authors critically reviewed the manuscript throughout the editorial process. All authors read and approved the final version of the manuscript submitted for publication. All authors agree to be accountable for all aspects of the work, ensuring the accuracy and integrity of the publication.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}